Brendan P. Eckelman - Chief Scientific Officer at Inhibrx Biosciences, Inc.

Insider Transactions and Holdings

Class	Num Shares	Value	Price $	Transaction Date	Ownership	Underlying Class
Common Stock	434K	$5.61M	$12.93	May 29, 2024	By the Eckelman Living Trust Dated February 5, 2014
Common Stock	40K	$517K	$12.93	May 29, 2024	By trust
Stock Option (right to buy)	175K			May 30, 2024	Direct	Common Stock

Showing 1 to 3 of 3 entries

Sym	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.